JEFFREY ADELGLASS, M.D., F.A.C.S.
CLINICAL RESEARCH STUDIES
Dallas | ft. worth TEXAS
Vaccines Can't Advance without Research
Current seasonal flu vaccines are usually only 60% effective at best, and they often perform poorly during years when the circulating flu strains doesn't match the strains selected for that year's vaccine.
Those who join this important study are contributing to research that could potentially impact flu vaccination effectiveness around the world.
Study Overview
The mRNA-1010-P101 Study is evaluating if an investigational mRNA vaccine is safe and effective in preventing the flu in adults. Flu vaccines based on mRNA technology could potentially provide several benefits compared to current vaccines, including the ability to respond to changes in influenza strains more quickly, stronger immune responses, and improved protection in older adults.
Participants in this study will be randomized to receive either the investigational vaccine or an already-approved seasonal influenza vaccine, called an active comparator. This allows researchers to study the safety and efficacy of the investigational vaccine against the flu compared to other standard vaccines that are currently in use.
The total length of study participation is approximately seven months. If you are interested in seeing if you may qualify to enroll, you will need to be evaluated to determine if the mRNA-1010-P101 Study is a good match for you.
To join the study, you must:
- Be at least 18 years of age and in generally good health
- Not be currently pregnant or planning to become pregnant during the study
- Not have been exposed to or infected with SARS-CoV-2 (the virus that causes COVID-19) within 14 days prior to the screening visit, unless you have been fully vaccinated for COVID-19
The study doctor willl explain additional requirements and answer any questions you may have. You have the right to withdraw from the study at any time for any reason. The study doctor or sponsor also has the right to discontinue your participation at any time in the interest of your safety or if you do not continue to meet eligibility requirements.
What to Expect
Your participation will last approximately seven months and includes phone calls and up to five visits to the study site.
- At your first visit after screening, you will receive an injection and be monitored at the study site for one hour afterward
- Your other three visits to the study site will happen one month, three months, and six months after the injection
- The study site will contact you via phone to discuss any changes in your health, medications you are taking, and non-study vaccinations you have received
- You will be asked to complete electronic diary (eDiary) entries following the injection and throughout your continued participation
About Vaccine Studies
It is very important to remember the following throughout the study:
- The investigational vaccine is experimental and has not yet been approved by the US Food and Drug Administration (FDA) -- this means we are still researching the product and we do not know if it is effective and safe to use
- Throughout the study, we will be monitoring participants closely for any side effects
currently enrolling subjects for
PAID CLINICAL RESEARCH participation
Thank You
for considering the mRNA-1010-P101 Study. By taking part in this study, you could contribute to the development of more-effective flu vaccines in the future.
To learn more, complete the form above, and call Research Your Health at (972) 746-2222.
Call 972-746-2222 Now to Schedule